Global evolution of inflammatory bowel disease across epidemiologic stages.
Lindsay Hracs, Joseph W Windsor, Julia Gorospe...
https://pubmed.ncbi.nlm.nih.gov/40307548Actively Recruiting
All Genders
ID07155148
Argentine Registry of Crohn's Disease and Ulcerative Colitis
Led by Grupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa · Updated on 2025-09-23
4250
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to create a comprehensive registry of patients with Inflammatory Bowel Disease (IBD) in Argentina, including both children and adults. The registry collects detailed demographic, clinical, and diagnostic information from routine medical care to better understand IBD in this population. It also evaluates safety aspects, such as infections, access to healthcare, and treatment effectiveness, including complications like flares, hospitalizations, and surgeries. The registry is observational, involving no experimental treatments or interventions. It is coordinated by multiple committees overseeing administration, scientific initiatives, and methodological support. Physicians across Argentina who manage IBD patients contribute data through a secure web platform. Participation is voluntary for both doctors and patients, with ethical approval and informed consent processes in place to protect patient privacy. Participants contribute data during routine clinical visits, which are uploaded and monitored centrally to ensure quality and completeness. Researchers analyze information on demographics, treatment safety, and clinical outcomes. The registry supports ongoing research projects to address important regional questions on IBD. Participation duration and follow-up depend on routine care, with data collection continuing over time to support epidemiological studies.
CONDITIONS
Brief Title
Argentine Registry of Crohn's Disease and Ulcerative Colitis
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Any patient diagnosed with IBD defined by validated diagnostic criteria
You will not qualify if you...
- Suspected IBD diagnosis without confirmation
- IBD patients with incomplete information about therapy and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm diagnosis and consent
Surveillance
Duration - Ongoing throughout the study period
Participants who undergo routine care for inflammatory bowel disease (IBD) are observed through data collection in the registry to capture demographic, clinical, and safety information.
Visits occur as part of routine care with data collected during regular clinical appointments
Trial Site Locations
Total: 1 location
1
Hospital Privado Universitario de Cordoba
Córdoba, Córdoba Province, Argentina, 5016
Actively Recruiting
Loading map...
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21).
Joyce W Y Mak, Yang Sun, Julajak Limsrivilai...
https://pubmed.ncbi.nlm.nih.gov/37231405Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera...
https://pubmed.ncbi.nlm.nih.gov/38340754Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study.
Pablo Andres Olivera, Domingo Balderramo, Juan Sebastian Lasa...
https://pubmed.ncbi.nlm.nih.gov/39549817High ulcerative colitis and Crohn's disease ratio in a population-based registry from Córdoba, Argentina.
Domingo Balderramo, Juan Trakal, Pablo Herrera Najum...
https://pubmed.ncbi.nlm.nih.gov/33531211